Immupharma (IMM)

 

Latest News

Holding(s) in Company

RNS Number: 2167X Immupharma PLC 17 February 2017 17 FEBRUARY 2017 NOTIFICATION OF INTEREST BY LEGAL & GENERAL ImmuPharma PLC (LSE:IMM) ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces that it has received notification by Legal & General Group Plc ("L&G") confirming its...

Update on Lupuzor Phase III Study

RNS Number: 0128V Immupharma PLC 25 January 2017 25 JANUARY 2017 ImmuPharma PLC ("ImmuPharma" or the "Company") Update on Lupuzor Pivotal Phase III Study Full Analysis of Patient Recruitment ImmuPharma PLC (LSE:IMM) , the specialist drug discovery and development company, is pleased to provide further details of patient participation ...

Change of Adviser

RNS Number: 8943U Immupharma PLC 24 January 2017 24 JANUARY 2017 ImmuPharma PLC ("ImmuPharma" or the "Company") Change of Adviser ImmuPharma PLC (LSE:IMM) , the specialist drug discovery and development company, is pleased to announce that it has appointed Northland Capital Partners as its Nominated Adviser and sole broker with im...

Holding(s) in Company

RNS Number: 9563S Immupharma PLC 29 December 2016 RNS: FOR IMMEDIATE RELEASE 29 DECEMBER 2016 ImmuPharma PLC ("ImmuPharma" or the "Company") TR1 NOTIFICATION OF MAJOR INTEREST ImmuPharma PLC (LSE:IMM) , the specialist drug discovery and development company, announces that it has received a TR-1 by Lanstead Ca...

All News

DateHeadlineSource
17-02-17Holding(s) in CompanyRNS
25-01-17Update on Lupuzor Phase III StudyRNS
24-01-17Change of AdviserRNS
29-12-16Holding(s) in CompanyRNS
22-12-16ImmuPharma completes Lupuzor patient recruitment StockMarketWire
22-12-16Update on Lupuzor Pivotal Phase III StudyRNS
16-11-16ImmuPharma update on cancer compound StockMarketWire
16-11-16Update on Cancer Compound IPP-204106 'Nucant'RNS
09-11-16Holding(s) in CompanyRNS
26-10-16Holding(s) in CompanyRNS
24-10-16ImmuPharma fundraising StockMarketWire
21-10-16Close of Accelerated BookbuildRNS
21-10-16ImmuPharma placing StockMarketWire
21-10-16Proposed Accelerated Bookbuild for Vendor PlacingRNS
30-09-16ImmuPharma losses increase StockMarketWire
30-09-16Half-year ReportRNS
14-09-16ImmuPharma update on Lupuzor study StockMarketWire
14-09-16UPDATE ON LUPUZOR'S PIVOTAL PHASE III STUDYRNS
07-09-16ImmuPharma to open new site in Lupuzor study StockMarketWire
07-09-16UPDATE ON LUPUZOR'S PIVOTAL PHASE III STUDYRNS
21-07-16Holding(s) in CompanyRNS
20-07-16Broker Forecast - Northland Capital issues a broker note on ImmuPharma PLCStockMarketWire
01-07-16Holding(s) in CompanyRNS
27-06-16Second Price Monitoring ExtnRNS
27-06-16Price Monitoring ExtensionRNS
20-06-16ImmuPharma appoints joint broker StockMarketWire
20-06-16Appointment of Joint BrokerRNS
09-06-16Why are Immupharma plc, Purplebricks Group plc and Roxi Petroleum plc among today’s major movers?Motley Fool
09-06-16Holding(s) in CompanyRNS
08-06-16Symposium with Lupuzors Inventor Prof. S MullerRNS
07-06-16ImmuPharma update on Lupuzor studyStockMarketWire
07-06-16Are Synairgen plc or Immupharma plc better investments than AstraZeneca plc?Motley Fool
07-06-16European Patients Commence Dosing in LupuzorRNS
02-06-16Director/PDMR ShareholdingRNS
31-05-16Holding(s) in CompanyRNS
26-05-16ImmuPharma resolutions passed at AGMStockMarketWire
26-05-16Result of AGMRNS
25-05-16Holding(s) in CompanyRNS
04-05-16ImmuPharma losses widenStockMarketWire
04-05-16Annual Financial Report & Notice of AGMRNS

RSS feeds

  • Editorial news feed for LSE:IMM Editorial
  • Regulatory news feed for LSE:IMM Regulatory